
UK hosts European BioEquity conference
Scottish Equity Partners and Scottish Widows Investment Partnership have joined Scottish Enterprise as part of the host committee for BioEquity Europe 2004. BioEquity Europe 2004 was hosted in Edinburgh on 17 and 18 May, the first time the event has been held in the UK. The conference represented the largest single gathering of professional financiers and potential funders for the life science industries in Europe over the last year. In Scotland the bioscience industry has an average growth rate of more than 20% per year and employs around 26,000 people. Brian Kerr, director of SEP's specialist healthcare & life sciences investment group, stated that the conference was more upbeat about the prospects for the life science industry than any time in the last two to three years and the general consensus amongst investors is cautiously optimistic. He went on to assert that the European bioscience industry is catching up with the US in terms of volume, although US investments still out numbered European investments around three to one. The values of investment rounds in Europe are generally on a par with the US in the sub-$50m range, although the US still sees the majority of rounds above this range. Kerr continued to outline that with the IPO market opening up in the UK the trend for trade sales to US biotech companies is likely to diminish.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Back to Top